Motomu Nakatake

Title: Motomu Nakatake: Innovator in Vaccinia Virus Research

Introduction

Motomu Nakatake is a prominent inventor based in Yonago, Japan. He has made significant contributions to the field of virology, particularly in the development of genetically engineered vaccinia viruses. With a total of 3 patents to his name, Nakatake's work focuses on innovative methods for cancer treatment and cell fusion induction.

Latest Patents

Nakatake's latest patents include groundbreaking inventions such as a vaccinia virus that induces cell fusion between infected cells. This invention provides a method for producing a vaccinia virus that is deprived of the K2L gene or the HA gene, which is mutated to induce cell fusion and cell death. Another notable patent involves genetically recombinant vaccinia viruses that are effective in preventing or treating cancer. This recombinant virus lacks functions of VGF and O1L and includes a gene encoding B5R with a deleted SCR domain. Additionally, he has developed a combination kit of two vaccinia viruses, each encoding IL-7 and IL-12, respectively, for enhanced therapeutic use.

Career Highlights

Throughout his career, Nakatake has worked with esteemed institutions such as Tottori University and Astellas Pharma GmbH. His research has significantly advanced the understanding and application of vaccinia viruses in medical treatments.

Collaborations

Nakatake has collaborated with notable colleagues, including Takafumi Nakamura and Hajime Kurosaki. These partnerships have contributed to the success and impact of his research endeavors.

Conclusion

Motomu Nakatake's innovative work in the field of vaccinia virus research showcases his dedication to advancing medical science. His patents reflect a commitment to developing effective treatments for cancer and enhancing our understanding of viral mechanisms.